Supernus Pharmaceuticals, Inc. (SUPN): Price and Financial Metrics


Supernus Pharmaceuticals, Inc. (SUPN)

Today's Latest Price: $17.99 USD

0.01 (-0.06%)

Updated Feb 28 4:00pm

Add SUPN to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 215 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

SUPN Stock Summary

  • With a one year PEG ratio of 1,000.7, Supernus Pharmaceuticals Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 95.19% of US stocks.
  • Supernus Pharmaceuticals Inc's stock had its IPO on May 1, 2012, making it an older stock than 28.78% of US equities in our set.
  • With a price/earnings ratio of 12.19, Supernus Pharmaceuticals Inc P/E ratio is greater than that of about merely 23.98% of stocks in our set with positive earnings.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Supernus Pharmaceuticals Inc are CRNT, ONDK, ENVA, SGH, and PRGS.
  • Visit SUPN's SEC page to see the company's official filings. To visit the company's web site, go to www.supernus.com.
SUPN Daily Price Range
SUPN 52-Week Price Range

SUPN Stock Price Chart More Charts


SUPN Price/Volume Stats

Current price $17.99 52-week high $42.29
Prev. close $18.00 52-week low $17.37
Day low $17.37 Volume 1,000,800
Day high $18.19 Avg. volume 531,802
50-day MA $23.43 Dividend yield N/A
200-day MA $27.01 Market Cap 943.81M

Supernus Pharmaceuticals, Inc. (SUPN) Company Bio


Supernus Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The company was founded in 2005 and is based in Rockville, Maryland.

SUPN Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$17.99$516.94 2548%

Below please find a table outlining a discounted cash flow forecast for SUPN, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Supernus Pharmaceuticals Inc ranked in the 92th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 2561% on a DCF basis. As for the metrics that stood out in our discounted cash flow analysis of Supernus Pharmaceuticals Inc, consider:

  • The compound growth rate in the free cash flow of Supernus Pharmaceuticals Inc over the past 4.66 years is 0.87%; that's higher than 92.39% of free cash flow generating stocks in the Healthcare sector.
  • Supernus Pharmaceuticals Inc's weighted average cost of capital (WACC) is 7%; for context, that number is higher than only 15.04% of tickers in our DCF set.
  • SUPN's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than only 15.04% of tickers in our DCF set.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%2496%
1%2522%
2%2548%
3%2574%
4%2600%
5%2626%

EGRX, QHC, THC, PTN, and LCI can be thought of as valuation peers to SUPN, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.


SUPN Latest News Stream


Event/Time News Detail
Loading, please wait...

SUPN Latest Social Stream


Loading social stream, please wait...

View Full SUPN Social Stream

SUPN Price Returns

1-mo -23.25%
3-mo -23.05%
6-mo -33.44%
1-year -56.26%
3-year -30.81%
5-year 94.28%
YTD -24.16%
2019 -28.60%
2018 -16.64%
2017 57.82%
2016 87.87%
2015 61.93%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.6888 seconds.